Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
Who can participate
Age range55 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant with or without subjective memory complaints, verified by a study partner, beyond what one would expect for age
✓. Normal memory function documented by scoring above education adjusted cutoffs on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale -Revised (the maximum score is 25):
✓. 9 for 16 or more years of education
✓. 5 for 8-15 years of education
✓. 3 for 0-7 years of education
✓. Mini-Mental State Exam score between 24 and 30 inclusive (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director)
✓. Clinical Dementia Rating = 0. Memory Box score must be 0
✓. Cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living
Exclusion criteria
✕
What they're measuring
1
Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)
Timeframe: 5 years
2
Rate of change in cognition as measured by the Logical Memory Test I and II
Timeframe: 5 years
3
Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE)
. Any significant neurologic disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities
✕. Screening/Baseline MRI brain scan with evidence of infection, infarction, or other focal lesions or multiple lacunes or lacunes in a critical memory structure
✕. Subjects that have any contraindications for MRI studies, including the presence of cardiac pacemakers, or metal fragments or foreign objects in the eyes, skin or body.
✕. Major depression, bipolar disorder as described in DSM-IV within the past 1 year. Psychotic features, agitation or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol.
✕. Currently treated with medication for obsessive-compulsive disorder or attention deficit disorder.
✕. History of schizophrenia (DSM IV criteria).
✕. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
✕. Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol.